# US 11,077,171 B2 · Immunotherapy against several tumors including gastrointestinal and gastric cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,077,171 B2 - Document ID: US11077171B2 - Status: Granted - Kind: B2 - Application number: 17/161,253 - Filed: 2021-01-28 - Published: 2021-06-03 - Granted: 2021-08-03 - Earliest claimed: 2010-03-19 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Jens Fritsche; Toni Weinschenk; Steffen Walter; Peter Lewandrowski; Harpreet Singh - Web page: https://patentgrep.com/patent/US11077171B2 ## CPC - A61K 38/1709: {from mammals} - A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] - A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase} - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 39/0011: {Cancer antigens} - A61P 35/00: Antineoplastic agents - C07K 7/06: having 5 to 11 amino acids - C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} - G01N 33/505: {involving T-cells} - A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells} - A61K 2039/572: {cytotoxic response} - A61K 2039/585: {wherein the target is cancer} - C07K 2319/00: Fusion polypeptide - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. ## Claims ### Claim 1 A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence of RYLWATVTI (SEQ ID NO: 16), wherein the peptide is in a complex with an MHC molecule. ### Claim 2 (depends on 1) The method of claim 1, wherein the T cells are autologous to the patient. ### Claim 3 (depends on 1) The method of claim 1, wherein the T cells are obtained from a healthy donor. ### Claim 4 (depends on 1) The method of claim 1, wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. ### Claim 5 (depends on 1) The method of claim 1, further comprising expanding T cells in vitro. ### Claim 6 (depends on 1) The method of claim 1, wherein the MHC molecule is a class I molecule. ### Claim 7 (depends on 1) The method of claim 1, wherein the composition further comprises an adjuvant. ### Claim 8 (depends on 7) The method of claim 7, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 9 (depends on 1) The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide. ### Claim 10 (depends on 9) The method of claim 9, further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells. ### Claim 11 (depends on 1) The method of claim 1, wherein the patient has gastric cancer. ### Claim 12 (depends on 1) The method of claim 1, wherein the patient has gastrointestinal cancer. ### Claim 13 (depends on 1) The method of claim 1, wherein the patient has colorectal cancer. ### Claim 14 (depends on 1) The method of claim 1, wherein the patient has pancreatic cancer. ### Claim 15 (depends on 1) The method of claim 1, wherein the patient has lung cancer. ### Claim 16 (depends on 1) The method of claim 1, wherein the patient has renal cancer. ### Claim 17 (depends on 7) The method of claim 7, wherein the adjuvant comprises IL-2. ### Claim 18 (depends on 7) The method of claim 7, wherein the adjuvant comprises IL-7. ### Claim 19 (depends on 7) The method of claim 7, wherein the adjuvant comprises IL-15. ### Claim 20 (depends on 7) The method of claim 7, wherein the adjuvant comprises IL-21.